What does this research mean for the field?

Combined treatment with high-dose simvastatin and bone marrow-derived mesenchymal stem cells significantly improves blood reperfusion and increases capillary density compared to either treatment alone in a mouse model of hindlimb ischemia. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

September 17, 2010Journal of Biomedical ScienceOpen Access

Augmentation of neovascularization in murine hindlimb ischemia by combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells transplantation

Q: What is the clinical evidence from this study?

Study design: Other. Population: Hindlimb ischemia (n=40). Intervention: Simvastatin and bone marrow-derived mesenchymal stem cells vs. Saline (vehicle). Primary outcome: Blood reperfusion (ischemic/normal hindlimb blood flow ratio) (p=<0.05).

View Full Paper

Ask AI

Bookmark

Key result

Combined simvastatin and MSCs improve blood reperfusion and capillary density over monotherapy in ischemic mice.

P<0.05
n=40

Why the study?

Combining high-dose simvastatin with bone marrow-derived mesenchymal stem cells delivery may improve prognosis in hindlimb ischemia, but this effect was not established.

Does combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells improve neovascularization in a mouse model of hindlimb ischemia?

Comparison

Combined simvastatin and MSCs vs simvastatin alone vs MSCs alone vs saline control

Design

Randomized preclinical study

Follow-up

21 days

Authors

YLYong LiCentral China Normal University DZDingguo ZhangSouthern University of Science and Technology YZYuqing ZhangNanjing University of Chinese Medicine

Discussion

Member takes

Implication

No change to clinical limb ischemia care; leaves open synergistic statin-MSC effects for future translational studies.

Structured PICO

Does combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells improve neovascularization in a mouse model of hindlimb ischemia?

Population

40 adult female mice with induced unilateral hindlimb ischemia, treated with simvastatin and/or mesenchymal stem cells and followed for 21 days.

Intervention

Combined therapy with local injection of 5 × 10^6 bone marrow-derived mesenchymal stem cells (MSCs) and oral simvastatin (20 mg/kg/d gavage) for 21 days

Comparator

Saline injection + saline gavage (control), simvastatin alone (20 mg/kg/d), or MSCs alone (5 × 10^6 cells)

Outcome

Blood flow assessed by laser Doppler imaging at day 0, 10, and 21 after surgerysurrogate

Main Result

p-value: p=<0.05

Combined therapy with high-dose simvastatin and bone marrow-derived MSCs augments functional neovascularization in a murine model of hindlimb ischemia.

Cite This Study

Li et al. (2010) studied Hindlimb ischemia (n=40). Simvastatin and bone marrow-derived mesenchymal stem cells vs. Saline (vehicle) was evaluated on Blood reperfusion (ischemic/normal hindlimb blood flow ratio) (p=<0.05). Combined treatment with high-dose simvastatin and bone marrow-derived mesenchymal stem cells significantly improved blood reperfusion and increased capillary density compared to either treatment alone or control in a mouse model of hindlimb ischemia.

synapsesocial.com/papers/6aab4dc493c64c9199bb09a3 https://doi.org/10.1186/1423-0127-17-75

View Full Paper

Ask AI

Bookmark

Augmentation of neovascularization in murine hindlimb ischemia by combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells transplantation

Discussion

Member takes

Implication

Structured PICO

Main Result

Cite This Study

Augmentation of neovascularization in murine hindlimb ischemia by combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells transplantation

Discussion

Member takes

Implication

Structured PICO

Main Result

Cite This Study

Also Consider

Also Consider